Align TechnologyXTER:AFW 89 EBITDA Margin % is 22.03% as of Mar. 2026, which is 3% below its 10-year median of 22.77. GuruFocus rates XTER:AFW with a GF Score™ of 89/100 and a GF Value™ of €212.06 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Align Technology ranks better than 77.94% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Align Technology's EBITDA for the
three
months ended in Mar. 2026 was €198 Mil. Align Technology's Revenue for the
three
months ended in Mar. 2026 was €900 Mil. Therefore, Align Technology's EBITDA margin for the quarter that ended in Mar. 2026 was 22.03%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Align Technology EBITDA Margin % Related Terms
Align Technology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Align Technology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:AFW vs SOLV, COO, BAX: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Align Technology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Align Technology EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Align Technology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Align Technology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Align Technology (XTER:AFW) has a EBITDA Margin % of 22.03% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Align Technology and its competitors. This is near median its historical median of 22.77. Over the past decade, Align Technology's EBITDA Margin % has ranged from 19.45 to 27.45. According to the industry distribution chart, Align Technology ranks #180 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 22.1%.
Is Align Technology's EBITDA Margin % too high?
Align Technology's current EBITDA Margin % of 22.03% is near median its 10-year median of 22.77. Over the past 10 years, this metric has ranged from a low of 19.45 to a high of 27.45. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Align Technology's value of 22.03% is 194.7% above this industry median. Based on the distribution chart, Align Technology ranks #180 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Align Technology has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Align Technology's EBITDA Margin % compare to SOLV and COO?
According to the Medical Devices & Instruments industry distribution chart, Align Technology ranks #180 out of 816 companies for EBITDA Margin %. This places Align Technology in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Align Technology's value of 22.03% is 194.7% above this benchmark. Historically, Align Technology's own EBITDA Margin % has ranged from 19.45 to 27.45 over the past decade. While the company's 10-year median is 22.77 vs. the industry median of 7.48, Align Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Align Technology's current EBITDA Margin % of 22.03% is 194.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Align Technology and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Align Technology's current EBITDA Margin % is 22.03%, which is near median its own 10-year median of 22.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Align Technology stock overvalued right now?
Based on GuruFocus' analysis, Align Technology (XTER:AFW) is currently considered Significantly Undervalued. The stock's GF Value™ is €212.06, compared to a current price of €149.05 — trading 29.7% below its estimated fair value. The current EBITDA Margin % is 22.03%, which is near median its 10-year median of 22.77 and 194.7% above the Medical Devices & Instruments industry median of 7.48. Align Technology's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Align Technology (XTER:AFW), the current EBITDA Margin % is 22.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Align Technology (XTER:AFW) Overvalued in 2026?
Based on GuruFocus' analysis, Align Technology stock appears to be undervalued.
The current stock price of €149.05 is trading 29.7% below its estimated GF Value™ of €212.06.
GuruFocus considers Align Technology to be Significantly Undervalued.
Key valuation signals for XTER:AFW:
EBITDA Margin %: 22.03% (near median its 10-year median of 22.77)
GF Value™: €212.06 vs. price of €149.05 (29.7% below fair value)
Industry Position: 194.7% above the Medical Devices & Instruments median (#180 of 816)
No single metric tells the full story. See the XTER:AFW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
89GF Score
Get the complete analysis for XTER:AFW
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:AFW has been successfully added to your 
